金陵药业: 金陵药业股份有限公司监事会关于第九届监事会第十八次会议相关事项的审核意见

Group 1 - The supervisory board of Jinling Pharmaceutical Co., Ltd. has reviewed and approved the adjustment of the repurchase price for the 2021 restricted stock incentive plan, confirming compliance with relevant laws and regulations [1] - The supervisory board agrees with the repurchase and cancellation of restricted stocks that have been granted but not yet released from restrictions, stating that the decision-making process is legal and compliant [1]